rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    URGN
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      UroGen: Opportunity Builds As Rough Patch Gets Brutal (NASDAQ:URGN)
      Nov 9Seeking AlphaURGN
      Oppenheimer reiterates Outperform on UroGen Pharma stock at $60
      Nov 5Investing.comURGN
      UroGen Pharma Ltd (URGN) (Q3 2026) Earnings Call Highlights: Zysturi's 35% Sequential Surge and ...
      Nov 5Yahoo FinanceURGN
      UroGen Pharma Ltd. Q3 2026 Earnings Call Summary
      Nov 5Yahoo FinanceURGN
      Earnings Beat Might Change The Case For Investing In UroGen Pharma (URGN)

      UroGen Pharma reported third quarter 2026 sales of US$89 million with a sharply reduced net loss of US$1.46 million, and year to date sales of US$212.42 million with a smaller loss of US$39.39 million. The combination of stronger reported sales and a significantly lower basic and diluted loss per share indicates that UroGen Pharma’s cost base and commercial execution are starting to better align. The following section examines how UroGen Pharma’s sharply narrowed quarterly net loss could...

      Nov 5Yahoo FinanceURGN
      Urogen Pharma Q3 Earnings Call Highlights
      Nov 4Yahoo FinanceURGN
      Why is UroGen Pharma stock sliding today?
      Nov 4Investing.comURGN
      UroGen Pharma Q3 2026 Earnings Call Transcript
      Nov 4BenzingaURGN
      Earnings call transcript: UroGen Pharma tops EPS view in Q3 2026, shares slide
      Nov 4Investing.comURGN
      UroGen Pharma earnings beat by $0.02, revenue fell short of estimates
      Nov 4Investing.comURGN
      Urogen Pharma (URGN) Reports Q3 Loss, Beats Revenue Estimates
      Nov 4Yahoo FinanceURGN
      UroGen Reports $68.0 Million of ZUSDURI Revenue and Provides Third Quarter 2026 Financial Results and Highlights
      Nov 4Yahoo FinanceURGN
      UroGen Pharma earnings up next: Can Zusduri fuel profit path?
      Nov 3Investing.comURGN
      UroGen Pharma to Present at the Guggenheim Securities 3rd Annual Healthcare Innovation Conference
      Nov 3Yahoo FinanceURGN
      H.C. Wainwright reiterates UroGen Pharma stock rating at buy
      Nov 3Investing.comURGN
      UroGen doses first patient in UGN-501 bladder cancer trial
      Nov 2Investing.comURGN
      UroGen Announces First Patient Dosed in Phase 1 Trial of UGN-501, an Investigational Next-Generation Oncolytic Virus for Non-Muscle Invasive Bladder Cancer
      Nov 2Yahoo FinanceURGN
      UroGen’s Final Results from Olympus Five-Year Follow-Up Study Reinforces Durable Response with JELMYTO in Patients with Low-Grade Upper Tract Urothelial Cancer
      Oct 28Yahoo FinanceURGN
      Oppenheimer reiterates Outperform on UroGen Pharma stock at $60
      Oct 28Investing.comURGN
      UroGen Pharma to Report Third Quarter 2026 Financial Results on Wednesday, November 4th, 2026
      Oct 27Yahoo FinanceURGN
      Why UroGen Pharma (URGN) Is Getting Fresh Attention Now
      Oct 20Yahoo FinanceURGN
      H.C. Wainwright reiterates UroGen Pharma stock rating on FDA filing acceptance
      Oct 20Investing.comURGN
      Exclusive BAC Article: UroGen Pharma; PDUFA June 14th 2027 UGN-103 LG-IR-NMIBC, Several BC Expansion Indications, And Catalsyts (NASDAQ:URGN)

      I believe that a good speculative biotech to go over for the Exclusive BAC Subscribers Article would be UroGen Pharma (URGN).

      Oct 19Seeking AlphaURGN
      UroGen Pharma Says FDA Accepts New Drug Application for UGN-103 in Bladder Cancer
      Oct 19Yahoo FinanceURGN
      FDA accepts UroGen’s drug application for bladder cancer
      Oct 19Investing.comURGN
      UroGen Announces FDA Acceptance of the New Drug Application for UGN-103, an Investigational Treatment for Adults with Recurrent LG-IR-NMIBC
      Oct 19Yahoo FinanceURGN
      UroGen Pharma: An Emerging GARP Stock
      Oct 13Seeking AlphaURGN
      UroGen Pharma CFO Chris Degnan sells $80,791 in shares
      Oct 9Investing.comURGN
      Here's Why You Should Add URGN Stock to Your Portfolio Now

      UroGen's Zusduri sales surge, Jelmyto revenues and advancing pipeline assets strengthen its shift toward a commercial growth story.

      Sep 30Yahoo FinanceURGN
      UroGen Pharma (URGN) Stock Looks Fairly Valued On Its Sales Base

      UroGen Pharma has seen its share price move sharply over recent years, which naturally puts a spotlight on whether the current valuation lines up with the sales the business is generating. For anyone looking at the stock today, the core issue is how much of that move can be explained by the company’s revenue base rather than by sentiment alone. Over the past 3 years the stock has delivered a gain of 188.5%, which raises the question of how closely that share price climb tracks the growth in...

      Sep 25Yahoo FinanceURGN
      Is UroGen’s (URGN) Commercial Engine Strong Enough To Fund Its Pipeline Ambitions?

      UroGen Pharma (NASDAQ:URGN) operates as a specialized oncology and urology therapeutics company anchored by proprietary sustained-release technology platforms. By developing localized drug delivery systems designed to retain therapeutics in targeted tissue sites for extended periods, the company addresses the significant clinical limitations of systemic toxicity and rapid clearance common in traditional cancer treatments. Its underlying […]

      Sep 23Yahoo FinanceURGN
      UroGen at H.C. Wainwright conference: Zusduri launch gains speed
      Sep 15Investing.comURGN
      Portfolio Change Alert: Adding UroGen Pharma To Model Portfolio (NASDAQ:URGN)
      Sep 14Seeking AlphaURGN
      UroGen at Cantor Fitzgerald conference: Zusduri launch gains traction
      Sep 10Investing.comURGN
      Jefferies reiterates UroGen Pharma stock rating on rival drug data
      Sep 10Investing.comURGN
      UroGen at Wells Fargo conference: launch gains and pipeline widen
      Sep 9Investing.comURGNWFC
      UroGen Pharma general counsel sells $64,618 in shares
      Sep 9Investing.comURGN
      Urogen Pharma: Upside After Bladder Cancer Launch (NASDAQ:URGN)
      Sep 9Seeking AlphaURGN
      UroGen Pharma CMO Mark Schoenberg sells $37,383 in shares
      Sep 9Investing.comURGN
      UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      PRINCETON, N.J., Sept. 04, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the grants of inducement restricted stock units (“RSUs”) to 19 new employees in connection with their employment with UroGen. These new team members will support the ongoing commercialization of JELMYTO® (mitomycin) for pyelocalyceal solution and ZUSDURI™ (mitomycin) f

      Sep 4Yahoo FinanceURGN
      UroGen Pharma to Present at Upcoming Investor Conferences

      PRINCETON, N.J., Sept. 02, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will participate in the following investor conferences in September. Wells Fargo 21st Annual Healthcare Conference Date / Time:September 9th, at 3:00 PM ETFormat:Fireside ChatLocation:Boston, MAWebcast Link:Here Cantor Global Healthcare Conference 2026 Date / T

      Sep 2Yahoo FinanceURGN
      Urogen Pharma Insider Sold Shares Worth $2,854,853, According to a Recent SEC Filing

      Mark Schoenberg, Chief Medical Officer, on August 20, 2026, sold 60,677 shares in Urogen Pharma (URG

      Aug 24Yahoo FinanceURGN
      Wall Street Analysts Think Urogen Pharma (URGN) Could Surge 27.14%: Read This Before Placing a Bet

      The consensus price target hints at a 27.1% upside potential for Urogen Pharma (URGN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

      Aug 21Yahoo FinanceURGN

      This is the newest page. Registered accounts read further back.